. Author manuscript; available in PMC: 2020 Jun 25.

Published in final edited form as: Blood Rev. 2010 Feb 11;24(2):69–82. doi: 10.1016/j.blre.2010.01.001

Table 4.

Response rates of single Lenalidomide in NHL.

Study	Status	Regimens	Patients	Results (%)
				ORR	CR/CRu
Wiernik et al. [65]	Phase II	25 mg QD, 21 of 28 days	Relapsed/refractory aggressive NHL (n = 50)	35	6
Zinzani et al. [66]	Phase II	25 mg QD, 21 of 28 days	Relapsed/refractory indolent NHL (n = 39)	41	13
Chanan-Khan et al. [68]	Phase II	25 mg QD, 21 of 28 days	Relapsed/refractory CLL (n = 45)	47	9
Ferrajoli et al. [69]	Phase II	10 mg QD, escalated to maximum of 25 mg QD	Relapsed/refractory CLL (n = 44)	32	7
Chen et al. [70]	Phase I	2.5 mg QD, escalated to 10 mg QD	Untreated CLL (n = 25)	65	0
Ferrajoli et al. [71]	Phase II	5 mg QD, escalated to maximum of 25 mg QD	Untreated CLL (n = 35)	54	0

CLL – chronic lymphocytic leukemia; CR – complete response; CRu – complete response unconfirmed; FL – follicular lymphoma; MAb – monoclonal antibody; NHL – non-Hodgkin lymphoma; oRr – overall response rate.